680 related articles for article (PubMed ID: 9458712)
1. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
2. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor.
Smiley PL; Stremler KE; Prescott SM; Zimmerman GA; McIntyre TM
J Biol Chem; 1991 Jun; 266(17):11104-10. PubMed ID: 1645725
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and 1-alkyl-2-acetyl-sn-glycerol by human endothelial cells.
Blank ML; Spector AA; Kaduce TL; Lee TC; Snyder F
Biochim Biophys Acta; 1986 May; 876(3):373-8. PubMed ID: 3707974
[TBL] [Abstract][Full Text] [Related]
5. Two different sites of action for platelet activating factor and 1-O-alkyl-2-O-methyl-sn-glycero-3-phosphocholine on platelets and leukemic cells.
Salari H; Dryden P; Howard S; Bittman R
Biochem Cell Biol; 1992 Feb; 70(2):129-35. PubMed ID: 1324692
[TBL] [Abstract][Full Text] [Related]
6. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
7. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
Koike H; Imanishi N; Natsume Y; Morooka S
Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
da Silva MB; Herion F; Raskinet R; David JL; Gustin P; Dessy C; Lekeux P
Zentralbl Veterinarmed A; 1996 Sep; 43(7):399-413. PubMed ID: 8921726
[TBL] [Abstract][Full Text] [Related]
10. Species-dependent differences of high affinity [3H]PAF-binding to platelets from humans and pigs and its inhibition by selected antagonists.
Ostermann G; Lorenz A; Hofmann B; Kertscher HP
J Lipid Mediat; 1991 Nov; 4(3):289-98. PubMed ID: 1662546
[TBL] [Abstract][Full Text] [Related]
11. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
Terashita Z; Imura Y; Nishikawa K
Biochem Pharmacol; 1985 May; 34(9):1491-5. PubMed ID: 2986648
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
13. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
Komuro Y; Imanishi N; Uchida M; Morooka S
Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
[TBL] [Abstract][Full Text] [Related]
14. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking.
Lehr HA; Weyrich AS; Saetzler RK; Jurek A; Arfors KE; Zimmerman GA; Prescott SM; McIntyre TM
J Clin Invest; 1997 May; 99(10):2358-64. PubMed ID: 9153277
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
16. 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle.
Touqui L; Jacquemin C; Dumarey C; Vargaftig BB
Biochim Biophys Acta; 1985 Jan; 833(1):111-8. PubMed ID: 3967037
[TBL] [Abstract][Full Text] [Related]
17. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
Grigoriadis G; Stewart AG
Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
[TBL] [Abstract][Full Text] [Related]
18. Activation of guinea pig peritoneal macrophages by platelet activating factor (PAF) and its agonists.
Hayashi H; Kudo I; Inoue K; Onozaki K; Tsushima S; Nomura H; Nojima S
J Biochem; 1985 Jun; 97(6):1737-45. PubMed ID: 2993272
[TBL] [Abstract][Full Text] [Related]
19. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes.
Hwang SB; Lee CS; Cheah MJ; Shen TY
Biochemistry; 1983 Sep; 22(20):4756-63. PubMed ID: 6313047
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.
Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L
Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
